Sugars in breastmilk could help treat infections, prevent preterm births

One of the most common bacteria that can affect pregnancies is Group B streptococcus (GBS). If left untreated, GBS infections can potentially lead to adverse effects, including neonatal pneumonia or preterm birth. Though treatments are available, they primarily rely on antibiotics, which can give rise to resistant strains. However, many of the compounds already present in human breast milk, such as human milk oligosaccharides (HMOs), naturally have antibacterial effects. Previously, Steven Townsend, Jennifer Gaddy and colleagues explored the antimicrobial effects of HMOs, finding that they could inhibit growth of GBS in vitro and in certain reproductive cells. But before the compounds could be used to boost existing antibiotics or become a new therapeutic option entirely, researchers need to show how the sugars work in many tissues and in vivo. So now, the team wanted to investigate HMO activity in GBS infections in pregnant mice and human tissues.

The team first analyzed the protective effects of HMOs on human tissue infected with GBS, using both ex vivofetal tissues and an organoid model of the vagina. When they added a mixture of HMOs designed to mimic the sugar composition in breast milk, the bacteria could not adhere and form colonies. The HMO mixture was then tested in pregnant mice infected with GBS. The treated mice had a relatively typical level of inflammation, reduced numbers of bacteria in several reproductive tissues, and experienced no instances of preterm births, ruptured membranes or maternal deaths. Taken together, these results demonstrate that HMOs can have antimicrobial effects without additional antibiotics. The researchers say that this work could allow for these sugars to be used as a viable therapeutic option to treat GBS infection and prevent adverse pregnancy outcomes.

The authors acknowledge funding from the National Science Foundation, the National Institutes of Health and the Department of Veterans Affairs.